Pharmaceutical

Multiple Paths to Commercial Success

FDA approves IND
PTSD Trial

University of Nebraska Medical Center (UNMC)

Drug: Nantheia ATL5

May 2022

Read Press Release

First Subject Enrolled
Radiculopathic Pain Trial

NYU Langone Hospital

Drug: Nantheia A1002

March 2022

Read Press Release

FDA Approves IND
Opioid Use Disorder Trial

Semel Institute UCLA

Drug: Nantheia ATL5

January 2022

Read Press Release

FDA approves IND
Opioid Use Disorder Trial

Mt. Sinai

Drug: Nantheia ATL5

October 2021

Read Press Release

IND filed with FDA
Opioid Use Disorder Trial

Semel Institute, UCLA

Drug: Nantheia ATL5

September 2021

Read Press Release

First Subject enrolled
PTSD Trial

NYU School of Medicine

Drug: Nantheia A1002

June 2021

Read Press Release

FDA approves IND
PTSD Trial

NYU Langone Hospital

Drug: Nantheia A1002

January 2021

Read Press Release

FDA approves IND
Radiculopathic Pain Trial

NYU Langone Hospital

Drug: Nantheia A1002

January 2021

Read Press Release

Dosing Completed
Phase I Clinical Study Trial

Hadassah Medical Hospital

Drug: Nantheia A1002

February 2020

Read Press Release

Trial Initiated
Phase I Clinical Study Trial

Hadassah Medical Hospital

Drug: Nantheia A1002

January 2020

Read Press Release